Drugs / MKK900
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07492706 | Apr 2026 overdue | respiratory syncytial virus infectious disease | MAXVAX Biotechnology Limited Liability Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MKK900 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07492706 ↗ |
| Route | Intramuscular | “Route of Administration : Intramuscular Injection” NCT07492706 ↗ |